Researchers have successfully develop single-atom editing technology that maximizes drug efficacy.

Now that the deadline for applications for the West Virginia First Foundation’s Initial Opportunity Grant program is closed, foundation staff and a panel of experts will begin work on vetting ...

Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first ...

FDA approves the biologics license application (BLA) that Dong-A submitted in 2023 for Imuldosa, a biosimilar referencing Stelara.